Patients and payers have long been predicted as the beneficiaries from the loss of exclusivity of some of the world’s biggest biological products. However, the longer experience of the complex biological drugs market suggests different dynamics.
When Sanofi lost the last in a long line of legal challenges that had blocked competitors from selling generic...